GERO
AI biotechnology company employing physics-based modeling and machine learning to understand the aging process and develop therapies targeting multiple age-related chronic diseases.
Notes
GERO is a biotechnology company applying physics-based approaches and artificial intelligence to understand the fundamental mechanisms of aging and develop therapeutics that target age-related diseases. The company's research is based on the idea that aging can be understood as a loss of resilience, a concept borrowed from physics and systems biology.
The company's AI platform analyzes large-scale biological data to identify drug targets and biomarkers associated with aging and age-related diseases. GERO has published research in top scientific journals including Nature Communications on topics such as the maximum human lifespan and biological age prediction.
GERO is funded by VitaDAO, a decentralized autonomous organization (DAO) focused on funding longevity research, as well as traditional venture investors in the longevity space.
Team
- Peter Fedichev, Ph.D. - Founder & CEO (physicist and longevity researcher)
- LinkedIn: linkedin.com/in/peterfedichev
- Team includes computational biologists, physicists, and AI researchers
Additional Research Findings
- Founded in 2015, headquartered in Singapore
- Physics-based approach to understanding aging
- AI platform for drug target discovery
- Published research on maximum human lifespan
- Funded by VitaDAO (decentralized longevity funding)
- Developed GeroSense app for biological age measurement
- Research focus: loss of resilience as aging mechanism
- Collaborations with academic research institutions
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| VitaDAO | Decentralized (Global) | dao | seed | 7 |